Skye Bioscience (SKYE): Can Shares Reach $2.00 With a +102% Gain?

Key Takeaways

• The central target used here is $2.00, a reverse-split-adjusted, market-structure objective grounded in the Nasdaq minimum-bid compliance effort — not an analyst consensus.
• At a latest close of roughly $0.99, reaching $2.00 would require a gain of about 102%, a very large move.
• Outstanding analyst targets are stale and contradictory — aggregators report averages from roughly $11 to $68 and ranges from $2 to $168 — and predate the August 2026 reverse split and merger, so they are not usable as a current target.
• The strongest supporting factor is the announced combination with Redx Pharma, which would form a fibrosis-focused company, Fibrx Therapeutics, backed by about $125 million in financing.
• The biggest risks are a sub-$1 share price that leaves the stock "deficient" under Nasdaq listing rules, ongoing cash burn, dilution risk, and execution uncertainty around the merger.
• The company's estimated earnings report follows around November 20, 2026, with total cash recently reported near $10 million.
• For more detail, explore the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
• You can also browse Trending AI Robots to see how AI-driven strategies are positioning across the market.

Setting the $2.00 Target in Context

Skye Bioscience, Inc. (SKYE) does not currently have a usable set of credible, current analyst price targets. Public aggregators report widely divergent figures — averages ranging from about $11 to $68, with individual targets spanning roughly $2 to $168 — but these figures largely predate the company's 1-for-8 reverse split (effective around August 24, 2026) and the August 14, 2026 announcement of a transaction with Redx Pharma. Because those targets have not been reconciled to the split-adjusted share count and the proposed merger, treating them as a consensus would be misleading.

The $2.00 objective used here is therefore a fallback target drawn from public discussion and market structure rather than analyst research. A 1-for-8 reverse split is typically executed to lift a sub-$1 share price back to a Nasdaq-compliant level of roughly $2.00 (about $0.25 pre-split). Reclaiming and holding the $2.00 level would signal that the split achieved its intended stabilizing effect. The more immediate compliance threshold is the $1.00 minimum bid price, which the stock currently sits just below. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Where SKYE Stands Today and the Path Forward

SKYE closed near $0.99 on November 6, 2026, with a micro-cap market capitalization of only about $4.38 million. The shares are down roughly 92% over the trailing 52 weeks, with a 52-week range of about $0.98 to $12.72. Moving from $0.99 to $2.00 would require an increase of approximately 102%, which is a very large move even for a high-beta (about 3.15) biotechnology stock.

The path is complicated by the pending transformation of the business. Under the announced agreement, the combined company would trade as Fibrx Therapeutics, focused on fibrosis, with Redx's GI-restricted pan-ROCK inhibitor RXC008 for fibrostenotic Crohn's disease as its lead program. Because the value of the combined entity will depend on a different asset and pipeline, the current share price reflects substantial uncertainty about deal completion, financing terms, and the new company's prospects.

Factors That Could Support Progress Toward $2.00

• The Redx Pharma transaction, if completed, would reposition SKYE around a new lead program and bring approximately $125 million in committed financing, which could materially strengthen the balance sheet and development runway.
• A sustained bid above $1.00 would resolve an immediate Nasdaq listing deficiency and could restore investor confidence in the company's continued exchange listing.
• The recently executed 1-for-8 reverse split was specifically designed to reset the share price higher, and regaining that reset level would be a positive structural signal.
• With total cash recently reported near $10 million, additional financing or reduced cash burn could ease near-term dilution concerns.

Key Risks That Could Block the Target

• The stock's sub-$1 price places it in Nasdaq deficiency territory, and failure to regain compliance could force further action, including additional reverse splits or delisting.
• SKYE reported a trailing net loss near $50 million with negative earnings per share (EPS) of roughly -$10, and a clinical-stage company with no product revenue remains dependent on external capital, creating ongoing dilution risk.
• The merger with Redx Pharma may not close, or terms could change, leaving shareholders exposed to the legacy obesity-focused asset and its development costs.
• Insider and institutional selling, along with an extremely thin float and low trading volume, can amplify downside volatility in a micro-cap name.

Technical Levels and Market Structure

The shares are trading near the bottom of their 52-week range, below the roughly $1.64 50-day moving average and the $4.69 200-day moving average. The $1.00 level represents the most important psychological and regulatory threshold, functioning as near-term resistance. Above that, the $2.00 reverse-split reset level is the next notable milestone. With short interest at only about 3.2% of shares outstanding, the structure points more to fundamental and listing concerns than to a crowded short that could fuel a squeeze. From what I see, this setup underscores the importance of monitoring compliance closely.

Time Horizon and What Investors Should Monitor

Analyst price targets, when current, typically reflect a roughly 12-month horizon, but the stale targets on SKYE carry no meaningful time discipline given the reverse split and proposed merger. Investors should instead track whether and when the Redx Pharma transaction closes, the terms of the combined company's Nasdaq listing, any effort to regain the $1.00 minimum bid, quarterly cash balances and burn rates, and the estimated earnings release around November 20, 2026. Updates on RXC008's development timeline and any additional financing announcements are also central to the outlook. I'm watching this closely as the situation evolves.

Using AI Daily Buy/Sell Signals in Practice

In my own analysis process, I often reference Tickeron's AI Daily Buy/Sell Signals to stay on top of shifts in volatile names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market conditions. For a micro-cap biotechnology stock navigating a merger and compliance hurdles, these signals can provide an additional layer of insight into potential entry or exit points without requiring constant manual chart reviews. I find it helpful for identifying how broader market sentiment might influence the stock amid its structural changes.

Final Assessment

Can SKYE reach $2.00? The $2.00 objective is a fallback, market-structure target reflecting the level a 1-for-8 reverse split was designed to achieve, not an analyst consensus. From a price near $0.99, the required move of about 102% is very large. The strongest support would come from closing the Redx Pharma transaction, securing the associated financing, and restoring Nasdaq compliance above $1.00. The principal obstacles are the listing deficiency, ongoing losses, dilution risk, and execution uncertainty around the merger. Given the absence of reliable current analyst targets and the company's transitional state, investors should weigh these structural factors rather than treat any single price figure as a forecast.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Notable companies

Industry description

Market Cap

High and low price notable news

Volume